Comment on 'Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer'-No support for de-escalation of immunotherapy

被引：1
|
作者：
Georgiou, Alexandros [1 ]
Minchom, Anna [1 ]
O'Brien, Mary [1 ]
机构：
[1] Royal Marsden Hosp Fdn Trust, London, England
来源：
EUROPEAN JOURNAL OF CANCER | 2019年 / 115卷
关键词：
DOCETAXEL; NIVOLUMAB; ATEZOLIZUMAB;
D O I：
10.1016/j.ejca.2019.04.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：24 / 26
页数：3
相关论文
共 50 条
  • [1] Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer
    Levy, Benjamin P.
    Giaccone, Giuseppe
    Besse, Benjamin
    Felip, Enriqueta
    Garassino, Marina Chiara
    Domine Gomez, Manuel
    Garrido, Pilar
    Piperdi, Bilal
    Ponce-Aix, Santiago
    Menezes, Daniel
    MacBeth, Kyle J.
    Risueno, Alberto
    Slepetis, Ruta
    Wu, Xiaoling
    Fandi, Abderrahim
    Paz-Ares, Luis
    EUROPEAN JOURNAL OF CANCER, 2019, 108 : 120 - 128
  • [2] Phase 2 Study of Pembrolizumab Plus CC-486 vs Pembrolizumab Plus Placebo in Previously Treated Patients with Advanced NSCLC
    Levy, B.
    Giaccone, G.
    Besse, B.
    Felip, E.
    Garassino, M.
    Domine, M.
    Garrido, P.
    Piperdi, B.
    Ponce Aix, S.
    Slepetis, R.
    Wu, X.
    Fandi, A.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1803 - S1804
  • [3] A phase II multicenter, randomized, placebo controlled, double-blind study of CC-486 plus pembrolizumab (pembro) vs pembro plus placebo (PBO) in previously treated patients (pts) with locally advanced/metastatic non-small cell lung cancer (NSCLC).
    Levy, Benjamin Philip
    Giaccone, Giuseppe
    Besse, Benjamin
    Begic, Damir
    Wu, Xiaoling
    Fandi, Abderrahim
    Paz-Ares, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Phase Ib Study of Crizotinib Plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation
    Patel, Sandip Pravin
    Pakkala, Suchita
    Pennell, Nathan A.
    Reckamp, Karen L.
    Lanzalone, Silvana
    Polli, Anna
    Tarazi, Jamal
    Robert-Vizcarrondo, Francisco
    ONCOLOGIST, 2020, 25 (07): : 562 - +
  • [5] A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non-small cell lung cancer
    Isono, Taisuke
    Kagiyama, Naho
    Shibata, Shun
    Nakajima, Hitomi
    Matsui, Yuma
    Takano, Kenji
    Nishida, Takashi
    Hosoda, Chiaki
    Kawate, Eriko
    Kobayashi, Yoichi
    Ishiguro, Takashi
    Takaku, Yotaro
    Kurashima, Kazuyoshi
    Yanagisawa, Tsutomu
    Takayanagi, Noboru
    THORACIC CANCER, 2021, 12 (09) : 1387 - 1397
  • [6] Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients
    Lin, Mao
    Luo, Haihua
    Liang, Shuzhen
    Chen, Jibing
    Liu, Aihua
    Niu, Lizhi
    Jiang, Yong
    JOURNAL OF CLINICAL INVESTIGATION, 2020, 130 (05): : 2560 - 2569
  • [7] Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer
    Gray, Jhanelle E.
    Saltos, Andreas
    Tanvetyanon, Tawee
    Haura, Eric B.
    Creelan, Ben
    Antonia, Scott J.
    Shafique, Michael
    Zheng, Hong
    Dai, Wenjie
    Saller, James J.
    Chen, Zhihua
    Tchekmedyian, Nishan
    Goas, Kristen
    Thapa, Ram
    Boyle, Theresa A.
    Chen, Dung-Tsa
    Beg, Amer A.
    CLINICAL CANCER RESEARCH, 2019, 25 (22) : 6623 - 6632
  • [8] Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer
    Kaira, Kyoichi
    Sunaga, Noriaki
    Imai, Hisao
    Kamide, Yosuke
    Koga, Yasuhiko
    Ono, Akihiro
    Kuwako, Tomohito
    Masuda, Tomomi
    Hisada, Takeshi
    Ishizuka, Tamotsu
    Yamada, Masanobu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (02) : 240 - 247
  • [9] Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer
    Kyoichi Kaira
    Noriaki Sunaga
    Hisao Imai
    Yosuke Kamide
    Yasuhiko Koga
    Akihiro Ono
    Tomohito Kuwako
    Tomomi Masuda
    Takeshi Hisada
    Tamotsu Ishizuka
    Masanobu Yamada
    International Journal of Clinical Oncology, 2016, 21 : 240 - 247
  • [10] JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer
    Ramalingam, Suresh S.
    Thara, Eddie
    Awad, Mark M.
    Dowlati, Afshin
    Haque, Basir
    Stinchcombe, Thomas E.
    Dy, Grace K.
    Spigel, David R.
    Lu, Sharon
    Iyer Singh, Nithya
    Tang, Yongqiang
    Teslenko, Iryna
    Iannotti, Nicholas
    CANCER, 2022, 128 (01) : 65 - 74
12345